Start Free Trial
Pricing
Log In
Log In
Upgrade browser for full Crunchbase experience. You're accessing Crunchbase in a browser that is no longer supported.
Learn More
Visgenx Logo
Visgenx Growth Score
31
CB Rank
73246
Heat Score
57
Visgenx develops therapeutics to protect against the loss of sight from retinal disorders.
Founded
obfuscation
PrivateVenture - Series Unknown San Diego, California, United States51-100 visgenxinc.com/
Biotechnology
Medical
Therapeutics
Overview

Visgenx
Total Funding
obfuscation
Growth Score
31
Heat Score
57

Total Funding
obfuscation
obfuscation
Venture - Series Unknown raised
obfuscation
Growth Score31
-25 pts
in past quarter
Heat Score 57
-6 pts
in past quarter

Company Performance Metrics

Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Learn More >
Recent Events
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience

About Visgenx

CB Rank
73246
Visgenx develops therapeutics to protect against the loss of sight from retinal disorders.
Founded
obfuscation
PrivateVenture - Series Unknown San Diego, California, United States51-100 visgenxinc.com/
Biotechnology
Medical
Therapeutics

Funding Rounds

Venture - Series Unknown
OBF
in
obfuscation
Venture - Series Unknown
OBF
in
obfuscation
Convertible Note
OBF
in
obfuscation

Key People

Details

Legal Name Visgenx, Inc.
Operating Status Active
Company Type For Profit
Founders  Daniel Chao, Dorota Skowronska, Martin Emanuele, Santosh J. Vetticaden
About the Company
Visgenx develops therapeutics to protect against the loss of sight from retinal disorders. Its programs are based on increasing the expression of a gene known as ELOVL2 which may regulate aging in cells critical for vision.
Diversity Spotlight 
Women Founded
Predictions & Insights

Growth Prediction

See this Growth Prediction
Top Contributing Factors
Growth Insight

Products & Services

ELOVL2 Gene Therapy for Dry AMD
A gene therapy designed to increase ELOVL2 expression in retinal cells to address dry age-related macular degeneration (AMD).
Synthetic AAV Non-viral Gene Delivery Platform
A synthetic vector system for gene delivery that enables large transgene delivery and reduced immunogenicity compared to viral vectors.

Unlock More with Crunchbase Pro
  • Full access to financial & funding data on unlimited profiles
  • Export up to 2k results/month for analysis
  • Track market signals on competitors, products, and R&D
  • Preview private company insights and predictions
Financials

Company Funding

Total Funding Amount 
obfuscation
Number of Funding Rounds 3
Unlock company funding data, including rounds, dates, amounts, and investors.
Announced Date  
Transaction Name  
Number of Investors  
Money Raised  
Lead Investors  
Funding Type  
obfuscation
Venture Round - Visgenx Logo
Venture Round - Visgenx
—
obfuscation
— Venture - Series Unknown
obfuscation
Venture Round - Visgenx Logo
Venture Round - Visgenx
—
obfuscation
— Venture - Series Unknown
obfuscation
Venture Round - Visgenx Logo
Venture Round - Visgenx
—
obfuscation
— Venture - Series Unknown
obfuscation
Venture Round - Visgenx Logo
Venture Round - Visgenx
—
obfuscation
— Venture - Series Unknown
obfuscation
Venture Round - Visgenx Logo
Venture Round - Visgenx
—
obfuscation
— Venture - Series Unknown

Funding Rounds

Total Funding Amount 
obfuscation
Number of Funding Rounds 3
Unlock company funding data, including rounds, dates, amounts, and investors.
Announced Date  
Transaction Name  
Number of Investors  
Money Raised  
Lead Investors  
Funding Type  
obfuscation
Venture Round - Visgenx Logo
Venture Round - Visgenx
—
obfuscation
— Venture - Series Unknown
obfuscation
Venture Round - Visgenx Logo
Venture Round - Visgenx
—
obfuscation
— Venture - Series Unknown
obfuscation
Venture Round - Visgenx Logo
Venture Round - Visgenx
—
obfuscation
— Venture - Series Unknown
obfuscation
Venture Round - Visgenx Logo
Venture Round - Visgenx
—
obfuscation
— Venture - Series Unknown
obfuscation
Venture Round - Visgenx Logo
Venture Round - Visgenx
—
obfuscation
— Venture - Series Unknown

Investors

Unlock company funding data, including rounds, dates, amounts, and investors.
Investor Name  
Lead Investor  
Funding Round  
Partners  
TCA Venture Group Logo
TCA Venture Group
—
Convertible Note - Visgenx Logo
Convertible Note - Visgenx
—
TCA Venture Group Logo
TCA Venture Group
—
Convertible Note - Visgenx Logo
Convertible Note - Visgenx
—
TCA Venture Group Logo
TCA Venture Group
—
Convertible Note - Visgenx Logo
Convertible Note - Visgenx
—
TCA Venture Group Logo
TCA Venture Group
—
Convertible Note - Visgenx Logo
Convertible Note - Visgenx
—
TCA Venture Group Logo
TCA Venture Group
—
Convertible Note - Visgenx Logo
Convertible Note - Visgenx
—
Market Intelligence
People
View Profiles & Contacts
Headcount 51-100 Employee Profiles 4 Board Members and Advisors 3 Contacts 4

Employee Profiles

Board Members and Advisors

News

News and Press

News•Nov 24, 2023
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•Nov 14, 2023
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•Jun 28, 2023
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•Jun 27, 2023
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
Access a complete feed of recent news and press, from product launches to leadership changes.
Technology
View Tech Report

Monthly Web Visits

63
50%
 in past month

Active Website Tech Count

14Visgenx is actively using 14 technologies for its website, according to BuiltWith. These include DMARC, U.S. Server Location, and  Microsoft Exchange Online.

Total IP

5The intellectual property of Visgenx includes 5 registered patents primarily in the 'Medical Or Veterinary Science; Hygiene' category, according to IPqwery.
Sub-Organizations
Frequently Asked Questions

Where is Visgenx's headquarters? Visgenx is located in San Diego, California, United States.Who invested in Visgenx? Visgenx is funded by TCA Venture Group.When was the last funding round for Visgenx? Visgenx closed its last funding round on
obfuscation
from a Venture - Series Unknown round.Who are Visgenx's competitors? Alternatives and possible competitors to Visgenx may include Opus Genetics, Nanoscope Therapeutics, and  Prime Medicine.How much funding has Visgenx raised to date? Visgenx has raised
obfuscation
.
Who We Are
What We Do
Helpful Links
AI Content may contain mistakes and is not legal, financial or investment advice. Learn more.
Terms of Service | Privacy Policy | Sitemap | © 2026 Crunchbase Inc. All Rights Reserved.
(5d42803 1)
|